GSDMD has also been investigated as a potential therapeutic target in cancer: treating endometrial or ovarian cancer cells with α-NETA, a reversible choline acetylcholine transferase inhibitor, induced pyroptosis via the GSDMD/caspase-4 pathway, and reduced tumor growth in mice (13). This evidence concerns the gene GSDMD and ovarian cancer.